Cargando…
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
OBJECTIVE: Recent large-scale randomised trials demonstrate that immunomodulators reduce cardiovascular (CV) events among the general population. However, it is uncertain whether these effects apply to rheumatoid arthritis (RA) and if certain treatment strategies in RA reduce CV risk to a greater ex...
Autores principales: | Solomon, Daniel H, Giles, Jon T, Liao, Katherine P, Ridker, Paul M, Rist, Pamela M, Glynn, Robert J, Broderick, Rachel, Lu, Fengxin, Murray, Meredith T, Vanni, Kathleen, Santacroce, Leah M, Abohashem, Shady, Robson, Philip M, Fayad, Zahi, Mani, Venkatesh, Tawakol, Ahmed, Bathon, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933165/ https://www.ncbi.nlm.nih.gov/pubmed/36450449 http://dx.doi.org/10.1136/ard-2022-223302 |
Ejemplares similares
-
Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
por: Giles, Jon T., et al.
Publicado: (2021) -
Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019) -
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020) -
Meaning of patient global assessment when joint counts are low in rheumatoid arthritis
por: Felson, David, et al.
Publicado: (2022) -
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)